Open AccessEmpagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus
Author(s) -
Hussein Al Jobori,
Giuseppe Daniele,
John M. Adams,
Eugênio Cersósimo,
Carolina SolisHerrera,
Curtis Triplitt,
Ralph A. DeFronzo
Publication year - 2018
Publication title -
the journal of clinical endocrinology and metabolism/journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2017-01838
Subject(s) - empagliflozin , glucose clamp technique , medicine , endocrinology , type 2 diabetes , type 2 diabetes mellitus , insulin , diabetes mellitus , insulin resistance , insulin sensitivity
To examine whether lowering plasma glucose concentration with the sodium-glucose transporter-2 inhibitor empagliflozin improves β-cell function in patients with type 2 diabetes mellitus (T2DM).